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INTRODUCTION
There are various extra-articular manifestations in juvenile
rheumatoid arthritis (JRA), like rheumatoid arthritis (RA).
And macrophage activation syndrome (MAS) is one of the life-
threatening complications of systemic onset JRA. It is asso-
ciated with excessive activation and uncontrolled prolifera-
tion of T lymphocytes and macrophages (1). This condition
occurs in a heterogeneous group of diseases including infec-
tious, neoplastic, hematologic and rheumatic disorders (2).
The clinical findings of MAS are acute and dramatic. Typi-
cally, patients become acutely ill at presentation with non-
remitting high fever, hepatosplenomegaly, lymphadenopa-
thy, severe cytopenia, liver disease, and intravascular coagu-
lation.
To our knowledge, a case of MAS associated with juvenile
rheumatoid arthritis has not been reported in Korea. We pre-
sent MAS in a patient with JRA successfully treated with
cyclosporine A.
CASE REPORT
A 29-yr-old man visited our clinic due to fever and jaun-
dice for one month. Three days ago, he visited the local clin-
ic and took oral prednisolone 20 mg but his symptoms and
elevated liver enzyme did not improve. He had been diag-
nosed with systemic onset JRA 16 yr ago and had stopped
the management of his own accord. The diagnosis of JRA
met the American College of Rheumatology 1977 criteria
for the classification of JRA as persistent intermittent fever
with skin rash polyarthritis existed for 3 months (3). Vital
signs at admission were; blood pressure of 120/80 mmHg,
heart rate of 76/min, respiration rate of 20/min, and body tem-
perature of 39℃. On physical examination, he had anemic
conjunctivae, icteric sclerae, dehydrated tongue, and hepato-
splenomegaly. He has multiple joint swelling and tenderness
and the joint radiography showed periarticular osteopenia and
erosions at proximal interphalangeal, metacarpophalangeal,
metatarsophalangeal, wrist and ankle joints, consist with ad-
vanced RA (Fig. 1). Complete blood count showed white
blood cell count 2,000/ L (neutrophil 28%; lymphocyte 47
%; monocyte 25%), hemoglobin 8.4 g/dL, hematocrit 24.2%
and platelet count 24,000/ L. Liver function test was abnor-
mal with total serum protein 5.7 g/dL, albumin 2.7 g/dL,
AST 311 IU/L (7-38), ALT 297 IU/L (4-43), total bilirubin
3.5 mg/dL, ALP 765 IU/L (40-129),  -glutamyl transferase
215 IU/mL (3-24) and LDH 3,695 IU/L (263-450). Renal
function test was also abnormal with BUN 100.2 mg/dL and
Cr 3.23 mg/dL. Other laboratory results were as follows: total
cholesterol 162 mg/dL, triglyceride 442 mg/dL and serum
ferritin 59,300 ng/mL (13-150). Erythrocyte sedimentation
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Macrophage Activation Syndrome in Juvenile Rheumatoid Arthritis
Successfully Treated with Cyclosporine A
: A Case Report
Macrophage activation syndrome (MAS) is one of the serious complications of juve-
nile rheumatoid arthritis (JRA) and recently, cyclosporine A has been found to be
effective in patients with corticosteroid-resistant MAS. A 29-yr-old male was admit-
ted with high fever and jaundice for one month. He was diagnosed as juvenile arthritis
16 yr ago. Physical and laboratory results showed hepatosplenomegaly, high fever,
pancytopenia and impaired liver and renal function tests, elevated triglyceride and
serum ferritin levels. Bone marrow biopsy showed hyperplasia of histiocytes with
active hemophagocytosis. He was diagnosed as MAS associated with juvenile rheu-
matoid arthritis and managed with high-dose corticosteroids initially, but clinical symp-
toms and laboratory findings did not improve immediately. Finally, he completely
recovered after treatment with cyclosporine A (3 mg/kg/day). 
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rate was 2 mm/hr and C-reactive protein was 5.25 mg/dL
(0-0.3). Coagulation tests and disseminated intravascular
coagulation profiles showed prothrombin time of 97%, acti-
vated partial thromboplastin time 37 sec (normal control 27
sec), fibrinogen 219 mg/dL, fibrin degradation product 10.6
g/mL (normal<5), antithrombin III 120% and D-dimer
13.51 mg/L (normal<1.0). Serological tests for viral infec-
tions, such as Epstein-Barr virus, cytomegalovirus and her-
pes simplex virus, revealed no sign of recent infections. Bac-
terial cultures of blood and urine were all negative. Bone mar-
row aspiration and biopsy showed marked increased histio-
cytes with active hemophagocytosis (Fig. 2). We diagnosed
him as having macrophage activation syndrome associated
with JRA. Intravenous pulsed methylprednisolone (1 g/day)
was administered followed high-dose oral prednisolone (1 mg/
kg/day). However, his symptoms and clinical signs did not
improve. Fever was sustained and abnormal laboratory find-
ings such as pancytopenia and impaired liver and renal func-
tion were not corrected. Then, oral cyclosporine A (CsA, 3
mg/kg/day) was added, and on next day after treatment with
cyclosporine A, fever disappeared. After 5 days, pancytope-
nia recovered with white blood cell count 5,800/ L (neutro-
phil 67.1%), hemoglobin 9.1 g/dL, hematocrit 26.1% and
platelet count 58,000/ L. Deteriorations of liver and renal
function were also normalized with AST 10 IU/L, ALT 24
IU/L, total bilirubin 0.85 mg/dL, BUN 26.5 mg/dL and Cr
1.10 mg/dL, and serum ferritin decreased to 1,500 ng/mL.
DISCUSSION 
In 1985, Hadchouel et al. reported that seven children with
JRA had a syndrome characterized by hemorrhage and neu-
rologic, hepatic, hematologic, and metabolic manifestations
(4). In 1993 Stephan et al. introduced the term MAS in fol-
low-up report originating from the same center (5). Recently,
it is recognized that MAS belongs to secondary hemophago-
cytic syndromes, histiocytic disorders associated with an un-
derlying systemic disease (6). Although MAS is most com-
mon in JRA, it can occur in patients with other rheumatic
Fig. 1. Radiographic images of hands, feet and hips. (A) Antero-
posterior view of both hands shows that periarticular osteopenia
and erosions at proximal interphalangeal, metacarpophalangeal,
radiocarpal and radioulnar joints. Ankylosis at both carpometacarpal
and intercarpal joints. (B) Anteroposterior view of both feet shows
the periarticular erosions at metatarsotarsal, tibiotalar, talonavicu-
lar and naviculocuneiform joints. (C) Anteroposterior view of both
hips shows that extensive pressure erosions in acetabuli and femo-
ral heads, resulting in protrusion of the acetabuli, especially in right
hip joint. 
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disorders such as adult-onset Still’s disease, Behcet’s disease
and systemic lupus erythematosus. Trigger factors are drugs
(aspirin, nonsteroidal anti-inflammatory drugs, gold prepa-
rations, methotrexate, tumor necrosis factor blocking agents)
and viral infections, particularly Epstein-Barr virus and her-
pes virus family (1).
The diagnostic hallmark of MAS is macrophage’s hemo-
phagocytosis in the bone marrow. The sensitivity and speci-
ficity of the main components of the clinical and laboratory
features of MAS were recently determined (7). Eighty-eight
patients with JRA who had 109 episodes diagnosed as MAS
were compared with control patients who had 35 episodes
of disease flare. The variables that showed the highest sensi-
tivity and specificity for MAS were the following: serum fer-
ritin ≥10,000 ng/mL, triglycerides ≥160 mg/dL, SGOT
≥40 IU/mL, fibrinogen ≤250 mg/dL, SGPT ≥40 IU/mL,
-glutamyl transferase ≥40 IU/mL, platelet count ≤150,000/
L, bone marrow aspirate showing macrophage hemophago-
cytosis, hepatomegaly, and splenomegaly. Variables that did
not prove sufficiently sensitive and specific included fever
≥38℃, lymphadenopathies, neurological manifestations,
arthritis, rash, hemorrhages, WBC ≤4,000/ L, ESR ≤50
mm/hr, LDH ≥900 IU/mL, bilirubin ≥1.2 mg/dL, and
serum sodium ≤130 mEq/L. In our case, the patient had
all components that showed the highest sensitivity and speci-
ficity for MAS, mentioned above.
The pathogenesis of MAS is still unclear. It has been exp-
lained that the over-activated T lymphocytes and macrophages
are found in various organ (2), and perforin deficiency and
some cytokines such as tumor necrosis factor- (TNF- ), inter-
leukin (IL)-1, IL-6, and interferon (IFN)- are playing roles
in the pathogenesis of MAS (8, 9). Perforin is a cytotoxic pro-
tein that lymphocytes secrete to kill virus-infected cells and
has a function that control the lymphocyte proliferation (10).
Therefore, the perforin deficiency may lead to persistent lym-
phocyte activation.
MAS is associated with significant morbidity and mortal-
ity in JRA. Therefore, early recognition and prompt man-
agement are very important. It has been suggested that the
initial treatment of choice in MAS is high-dose corticosteroid.
But, MAS may appear to be corticosteroid resistant. Recent-
ly, cyclosporine A proved effective in treating severe or cor-
ticosteroid-resistant MAS (5, 11, 12). In most patients with
MAS described by Mouy et al. (11) and Ravelli et al. (12), fever
resolved within 24 hr and laboratory abnormalities within a
few days. Cyclosporine A is a cyclic polypeptide immunosup-
pressant. The mechanism of action of cyclosporine A is not
fully known. However, it is believed to exert its major effects
by the early steps in T-cell activation. In addition, it may in-
hibit the production of IL-2 and IFN- and the expression
of the receptor site for IL-2 on T lymphocytes. Cyclosporine
A has also been shown to inhibit expression of inducible nitric
oxide (NO) synthase and cyclooxygenase-2 in macrophages,
leading to decreased production of NO and prostaglandin E2
(13). Furthermore, cyclosporine A inhibits the expression of
key cell surface co-stimulatory molecules. Thus, it can alter
the antigen-presenting function of dendritic cells for T cell
activation (14). In several cases of MAS, increased serum lev-
els of TNF- have been reported (5) and TNF- is thought
to play a central role in the pathogenesis of MAS. From this
point of view, it has been hypothesized that anti-TNF- agents
may be effective therapy for MAS. Prahalad et al. (15) des-
cribed a patient with MAS and JRA successfully treated with
the anti-TNF- agent, etanercept. 
The present case shows that MAS is a severe complication
of JRA and is dramatically recovered after management with
cyclosporine A. When high fever with pancytopenia, and
multiorgan dysfunction develop in a patient with JRA, MAS
should be considered. To our knowledge, this is the first case
report of MAS in a patient with JRA in Korea.
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